Trial Profile
Efficacy and safety of repaglinide, Glurenorm [gliquidone] and Glucobay [acarbose] in Chinese subjects with type 2 diabetes mellitus
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Feb 2017
Price :
$35
*
At a glance
- Drugs Repaglinide (Primary) ; Acarbose; Gliquidone
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 06 May 2009 Actual patient number (131) added as reported by ClinicalTrials.gov.
- 06 May 2009 Actual end date (Sep 2004) added as reported by ClinicalTrials.gov.
- 20 Dec 2007 New trial record.